Group 1: Company Buybacks - Jianbang Co. plans to repurchase shares worth between 15 million to 30 million yuan [2] - Huayuan Holdings intends to buy back no less than 30 million yuan and up to 60 million yuan of its shares [2] - China Jushi's controlling shareholder, Zhen Shi Group, plans to increase its stake by 550 million to 1.1 billion yuan [2] Group 2: Company Sell-offs - Changchuan Technology's shareholders plan to reduce their holdings by no more than 2.04% [2] - Bofei Electric's controlling shareholder and actual controller's concerted action plan to reduce holdings by no more than 2.95% [2] - Three executives of Dongfang Wealth intend to collectively sell no more than 334,990 shares [2] - ST Weiming's shareholder Gao Bolin and concerted actors plan to reduce holdings by no more than 3% [2] - Longqi Technology's shareholder Suzhou Shunwei has cumulatively reduced holdings by 4.09% [2] - Yanao Co.'s shareholder Wang Ping plans to reduce holdings by no more than 1.49% [2] - Data Port's shareholder Ningbo Ruixi plans to reduce holdings by no more than 3% [2] - Maoye Commercial's controlling shareholder's concerted action sold 2 million shares through block trading [2] - Jihong Co.'s controlling shareholder and concerted actors plan to reduce holdings by no more than 2.93% [2] - Fangyuan Co.'s shareholder Pingfang Yili plans to reduce holdings by no more than 1% [2] - ST Dehao's shareholder Bengbu Xinrui plans to reduce holdings by no more than 1.47% [2] - Sanjiang Shopping's second-largest shareholder reduced holdings by 5.4768 million shares from November 27 to 28 [2] - Yinuosi's shareholder Zhangjiang Biomedical Base plans to reduce holdings by no more than 1% [2] - Haopeng Technology's shareholder Zhuhai Anhao plans to reduce holdings by no more than 0.32% [2] - Shenqi Pharmaceutical's shareholder Zhang Zhijun plans to reduce holdings by no more than 3% [2] - Haimu Star's shareholder Tai'an Haihe plans to reduce holdings by no more than 3% [2]

Core Viewpoint - The company announced the appointment of two new vice presidents, Li Yan and Tang Napin, by the board of directors [1] Group 1 - The board of directors approved the hiring of Li Yan as vice president [1] - The board of directors approved the hiring of Tang Napin as vice president [1]

Core Points - Yinos's announcement on November 28 indicates that Zhangjiang Biopharmaceutical Base holds 11,020,753 shares of Yinos, representing 7.82% of the total share capital [2] - Zhangjiang Biopharmaceutical Base plans to reduce its holdings by up to 1,409,796 shares, which is no more than 1.00% of the total share capital, within three months after the announcement [2] - The reduction will be executed through centralized bidding and will not exceed 1.00% of the total shares within any consecutive 90-day period [2]

Group 1 - The company Yinos (SH 688710) announced plans to reduce its shareholding by up to approximately 1.41 million shares, which represents no more than 1% of the total share capital, within three months starting from 15 trading days after the announcement [1] - The share reduction will be conducted through centralized bidding, with the selling price determined by market conditions. Adjustments will be made to the reduction plan in case of any corporate actions such as dividends or stock splits during the implementation period [1] - As of the report, Yinos has a market capitalization of 6.3 billion yuan [1] Group 2 - For the fiscal year 2024, Yinos's revenue composition is as follows: non-clinical CRO accounts for 95.42%, clinical CRO accounts for 4.11%, other business segments account for 0.38%, and other operations account for 0.09% [1]

Group 1 - The company Yinos (SH 688710) announced the appointment of Li Yan and Tang Napin as vice presidents, approved by the board of directors [1] - For the year 2024, Yinos's revenue composition is as follows: non-clinical CRO accounts for 95.42%, clinical CRO accounts for 4.11%, other businesses account for 0.38%, and other services account for 0.09% [1] - The current market capitalization of Yinos is 6.3 billion yuan [2]

Core Viewpoint - Yinos (688710.SH) announced a plan to reduce its shareholding through centralized bidding within three months after the announcement, with a maximum reduction of 1.4 million shares, accounting for no more than 1% of the total share capital [1] Summary by Categories - **Share Reduction Plan** - The company plans to reduce its holdings by no more than 1.4 million shares [1] - This reduction represents up to 1% of the company's total share capital [1] - The reduction will occur within three months after the announcement, starting 15 trading days from the disclosure date [1] - **Trading Restrictions** - The total number of shares reduced within any consecutive 90 natural days will not exceed 1% of the company's total shares [1]

Core Viewpoint - Yinuo Si (688710.SH) announced a plan to reduce its shareholding through centralized bidding within three months after the announcement, with a maximum reduction of 1.4 million shares, accounting for no more than 1% of the total share capital [1] Summary by Categories - **Share Reduction Plan** - The company plans to reduce its holdings by no more than 1.4 million shares [1] - This reduction represents up to 1% of the company's total share capital [1] - The reduction will occur within three months after the announcement, starting 15 trading days from the disclosure date [1] - **Trading Restrictions** - The total number of shares reduced within any consecutive 90 calendar days will not exceed 1% of the company's total shares [1]

Core Viewpoint - Yinos (688710.SH) plans to reduce its shareholding through centralized bidding within three months after the announcement, indicating a strategic move to manage its equity structure [1] Group 1: Share Reduction Plan - The company intends to reduce its holdings by no more than 1.4098 million shares, which represents up to 1.00% of the total share capital [1] - The reduction will occur within a period of three months from the announcement date, starting 15 trading days after the disclosure [1] - The total number of shares reduced within any consecutive 90-day period will not exceed 1.00% of the company's total shares [1] Group 2: Pricing Mechanism - The reduction price will be determined based on market prices at the time of the transaction [1]

证券代码：688710 证券简称：益诺思 公告编号：2025-044 上海益诺思生物技术股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，上海张江生物医药基地开发有限公司（以下简称"张江 生药基地"）持有上海益诺思生物技术股份有限公司（以下简称"公司"）11,020,753 股，占公司总股本的 7.82%。 减持计划的主要内容 张江生药基地计划自本公告披露之日起 15 个交易日后的 3 个月内，通过集 中竞价交易方式减持其所持有的公司股份数量不超过 1,409,796 股，占公司总股 本的比例不超过 1.00%，且在任意连续 90 个自然日内，减持的股份总数不超过 公司股份总数的 1.00%。减持价格按市场价格确定，若在上述减持计划实施期间， 公司发生派发红利、送红股、转增股本、增发新股或配股等股本变动、除权除息 事项，则上述减持计划将作相应调整。 公司于 2025 年 11 月 28 日收到股东张江生药基地出具的《关于股 ...

附件： 上海益诺思生物技术股份有限公司（以下简称"公司"）于2025年11月28 日召开第三届董事会第二十一次会议，审议通过了《关于聘任公司副总裁的议案》。 具体情况如下： 经公司总裁提名，董事会提名委员会审议通过，公司董事会同意聘任李燕女 士、汤纳平先生（简历详见附件）担任公司副总裁。任期自董事会审议通过之日 起至第三届董事会届满之日止。 李燕女士、汤纳平先生高级管理人员的任职资格符合相关法律、行政法规、 规范性文件的相关规定，不存在《公司法》《公司章程》规定的不宜担任上市公 司高级管理人员的情形；不存在被中国证券监督管理委员会确定为市场禁入者的 情况；不存在被上海证券交易所认定不适合担任上市公司高级管理人员的其他情 形。 特此公告！ 上海益诺思生物技术股份有限公司董事会 2025年11月29日 证券代码：688710 证券简称：益诺思 公告编号：2025-042 上海益诺思生物技术股份有限公司 关于聘任公司副总裁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、李燕女士个人简介 李燕女士，1976年生，中国国 ...